A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT02245620
- Locations
- 🇺🇸
The University of Washington Medical Center, Seattle, Washington, United States
Safety and Pharmacokinetic (PK) Study of Oral Bendavia Administered for 7 Days
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-02-08
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01786915
- Locations
- 🇺🇸
Clinical Pharmacology of Miami Inc, Miami, Florida, United States
Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2012-12-24
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT01755858
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Phase 1 Study Examining the Pharmacokinetics and Tolerability of a Single Oral Dose of Bendavia (MTP-131)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-12-21
- Last Posted Date
- 2013-02-06
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT01754818
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events
- First Posted Date
- 2012-04-06
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT01572909
- Locations
- 🇩🇪
Universitaetsklinikum Freiburg, Freiburg, Germany
🇭🇺Honvédkórház-Állami Egészségügyi Központ, Budapest, Hungary
🇭🇺Semmelweis Egyetem Kardiológiai Központ, Városmajor u. 68, Budapest, Hungary
The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT01518985
- Locations
- 🇺🇸
Clinical Pharmaology of Miami, Miami, Florida, United States
Study to Assess the Pharmacodynamic Effects of Unfractionated Heparin (UFH) in Healthy Volunteers With and Without Bendavia
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01513200
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States
Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults
- First Posted Date
- 2010-05-04
- Last Posted Date
- 2010-11-18
- Lead Sponsor
- Stealth BioTherapeutics Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01115920
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, Inc., Miami, Florida, United States
© Copyright 2024. All Rights Reserved by MedPath